Ondine demonstrates high Periowave(TM) efficacy in key tissue-invasive pathogen

    - abstract to be presented at IADR conference, New Orleans -

    VANCOUVER, March 23 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) today announced presentation of a late-breaking abstract at the
prestigious International Association of Dental Research (IADR) annual meeting
in New Orleans. This publication showed that the Periowave(TM)
photodisinfection system is capable of eradicating one of the most elusive and
difficult to kill periopathogens, Actinobacillus actinomycetemcomitans (Aa).
Aa is a Gram-negative facultative anaerobe that infects periodontal tissues
themselves rather than dental biofilms, making the bacterium extraordinarily
difficult to eradicate with routine mechanical debridement.
    "In a recent in vitro study, Periowave(TM) proved capable of killing up
to 99.999% of biofilm-based periopathogens such as P. gingivalis and
F. nucleatum in both planktonic and biofilm culture, and eradicating over 99%
of Aa in 60 seconds," said Dr. Cale Street, Director of Research for Ondine
Research Laboratories. "This was an important and gratifying outcome, because
it has been known for many years that Aa is implicated in cases where disease
is unresponsive to standard mechanical debridement. This finding may explain
why Periowave(TM) improved outcomes in several clinical cases where routine
mechanical debridement as well as antibiotic therapy had been carried out for
years, with only marginal results."
    As previously released, three other poster abstracts based on the
clinical trial conducted by Loma Linda University will also be presented at
the conference by the Principle Investigators of the study.
    The 85th Annual IADR/AADR conference runs from March 21-24th, 2007 in New
Orleans and is expected to attract 5000 dental researchers from around the
world who are dedicated to the prevention and treatment of oral and dental

    About Periowave(TM) and Photodisinfection (PDD)
    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and one
or more lasers are used to activate the compounds and complete the
disinfection. The Photodisinfection technologies were developed by Professor
Michael Wilson and colleagues at the Eastman Dental Institute, University
College London, and licensed to Ondine by UCL Biomedica PLC, University
College London. Additional information about Periowave(TM) is available at

    About Ondine Biopharma Corporation:
    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance.
    The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Redmond, Washington, USA, a sales and marketing
subsidiary in York, Pennsylvania, and an international office in St Michael,
Barbados. For additional information, please visit the Company's website at:

    Forward-Looking Statements:
    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890